MedTrace Logo

Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old

NCT05518201 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-04-17

No results posted yet for this study

Summary

To evaluate the safety and tolerability of the 9vHPV vaccine in Chinese healthy male aged 9 to 45 years.

Conditions

  • Penile Cancer
  • Anal Cancer
  • PIN-1
  • PIN-2
  • PIN-3
  • AIN1
  • AIN2
  • AIN3
  • Genital Wart

Interventions

BIOLOGICAL

Placebo among 18-45 yrs

Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).

BIOLOGICAL

Placebo among 9-17 yrs

Subjects received 3 doses of placebo according to a 0, 2, 6-month schedule (0.5mL/each dose).

Sponsors & Collaborators

  • Shanghai Bovax Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Ting Huang · Sichuan Provincial Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
9 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-23
Primary Completion
2023-11-20
Completion
2023-11-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05518201 on ClinicalTrials.gov